Abstract 11322: Maternal Triglyceride-Glucose Index and Adverse Pregnancy Outcomes: Association and Prognostic Performance in a Systematic Review and Meta-Analysis
Ochiq kirish: yoʻq
Annotatsiya
Background: Pregnancy is marked by metabolic adaptation, and progressive insulin resistance contributes to maternal and fetal complications. The triglyceride-glucose (TyG) index, derived from fasting triglyceride and glucose levels, is a practical surrogate of insulin resistance, but its prognostic role during pregnancy remains uncertain. Objective: To examine the association between maternal TyG levels and adverse pregnancy outcomes and summarize prognostic performance for selected obstetric complications. Methods: We searched PubMed, Embase, and Cochrane databases from inception to May 2026 for studies evaluating TyG as a prognostic tool during pregnancy. We computed odds ratios (ORs) for binary outcomes, with 95% confidence intervals (CI). Diagnostic accuracy measures and summary receiver operating characteristic (SROC) analyses were also calculated. Results: Twenty-one studies involving 195,787 pregnant women were included. Studies that assessed TyG in the first trimester included 162,237 women (82.9% of the total population), corroborating its potential applicability as an early-pregnancy risk-stratification tool. Higher TyG levels were associated with gestational diabetes mellitus (OR 2.66; 95% CI 2.21-3.20; Figure 1A), preeclampsia (OR 2.31; 95% CI 1.60-3.33; Figure 1B), gestational hypertension (OR 1.73; 95% CI 1.44-2.09), macrosomia (OR 1.61; 95% CI 1.20-2.17), LGA (OR 1.60; 95% CI 1.44-1.78), and preterm birth (OR 1.47; 95% CI 1.26-1.72). Prognostic performance was moderate for composite adverse outcomes (pooled sensitivity 77.2% [95% CI, 64.6-86.3], pooled specificity 57.9% [95% CI, 38.9-74.8], and an AUC of 0.71 [95% CI, 0.61-0.81; Figure 2], with a DOR of 4.74 [95% CI, 2.99-7.53]), with modest-to-moderate performance for macrosomia (AUC 0.70) and GDM (AUC 0.64). No significant subgroup differences were found by gestational timing. Conclusions: Elevated maternal TyG levels were associated with multiple adverse pregnancy outcomes and demonstrated moderate prognostic performance. As a low-cost and widely available biomarker, TyG may serve as a practical first-trimester tool for cardiometabolic risk stratification and identification of high-risk pregnancies, warranting further prospective evaluation.
Hali tarjima qilinmagan